Evidence map›Paper›PMID 39258792›Full record

ReviewFuture oncology (London, England)2024

Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review.

August C Anderson, Joel Ho, Evan T Hall, Raquibul Hannan, Jay J Liao, Alexander V Louie, Ting Martin Ma, Sarah P Psutka, Ramesh Rengan, Shankar Siva and 9 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

August C AndersonUniversity of Washington, Department of Radiation Oncology, Seattle, WA 98195, USA.ORCID 0000-0002-2850-3617
Joel HoPfizer Inc., Bothell, WA 98011, USA.
Evan T HallUniversity of Washington, Division of Hematology & Oncology, Seattle, WA 98195,USA.
Raquibul HannanThe University of Texas Southwestern Medical Center, Radiation Oncology, Dallas, TX 75235, USA.
Jay J LiaoUniversity of Washington, Department of Radiation Oncology, Seattle, WA 98195, USA.
Alexander V LouieSunnybrook Health Sciences Centre, Department of Radiation Oncology, Toronto, ON, M4N 3M5, Canada.
Ting Martin MaUniversity of Washington, Department of Radiation Oncology, Seattle, WA 98195, USA.
Sarah P PsutkaFred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA 98195, USA.
Ramesh RenganUniversity of Washington, Department of Radiation Oncology, Seattle, WA 98195, USA.
Shankar SivaPeter MacCallum Cancer Centre, Division of Radiation Oncology & Cancer Imaging, Melbourne, VIC, 3052, Australia.
Anand SwaminathJuravinski Cancer Centre, Radiation Therapy, Hamilton, ON, L8V 5C2, Canada.
Lisa TachikiUniversity of Washington, Division of Hematology & Oncology, Seattle, WA 98195,USA.
Chad TangThe University of Texas MD Anderson Cancer Center, Genitourinary Radiation Oncology, Houston, TX 77030, USA.
Bin Sing TehHouston Methodist Hospital, Radiation Oncology, Houston, TX 77030, USA.
Joseph TsaiUniversity of Washington, Department of Radiation Oncology, Seattle, WA 98195, USA.
Scott S TykodiUniversity of Washington, Division of Hematology & Oncology, Seattle, WA 98195,USA.
Emily WegUniversity of Washington, Department of Radiation Oncology, Seattle, WA 98195, USA.
Nicholas G ZaorskyUniversity Hospitals Seidman Cancer Center, Case Western Reserve University, Department of Radiation Oncology, Cleveland, OH 44106, USA.
Simon S LoUniversity of Washington, Department of Radiation Oncology, Seattle, WA 98195, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic renal cell carcinoma (RCC) can present with oligometastatic disease and/or develop oligoprogression following systemic therapy. Cytoreductive and focal metastasis-directed therapy options include resection, stereotactic ablative radiation and thermal ablation. Aggressive focal therapy may allow delay in initiation of or modification to systemic therapy and improve clinical outcomes. In this narrative review we synthesize current practice guidelines and prospective data on focal therapy management options and highlight future research. Patient selection and the choice of focal treatment techniques are controversial due to limited and heterogeneous data and patients may benefit from multidisciplinary evaluation. Prospective comparative trials with clearly defined inclusion criteria and relevant end points are needed to clarify the risks and benefits of different approaches.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsCombined Modality TherapyDisease ManagementDisease ProgressionHumansNeoplasm MetastasisRadiosurgeryTreatment Outcomecytoreductionimmunotherapymetastasis-directed therapyoligometastaticoligoprogressiveRCCrenal cell carcinomaSABRSBRT

Identifiers

PMID39258792
PMCPMC11534104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.